Telehealth & Wellness Platform
Helping People Live Better
Helping People Live Better
The wellness and “longevity” market for injectables—specifically GLP-1s, peptides, and hormone therapies (TRT)—is currently one of the fastest-growing sectors in global healthcare. The growth has been primarily fueled by the “Ozempic effect.”
The public has become more educated about proactively addressing wellness concerns rather than relying on reactive treatment approaches. This shift has created a multi-billion dollar surge in demand for these therapies.
![Support](https://magenta-parrot-644780.hostingersite.com/wp-content/uploads/2026/04/WhatsApp_Image_2026-04-10_at_11.03.13_PM__2_-removebg-preview.png")
Market Size & Growth Projections (2024–2030)
| Category | 2024 Market Size | 2030 Projected | 5-Year CAGR | Key Growth Drivers |
|---|---|---|---|---|
| GLP-1 Agonists | $54.8 Billion | $150B – $268B | ~17% – 31% | Obesity epidemic, telehealth expansion, broader medical use |
| Peptide Therapeutics | $45.7 Billion | $76.8 Billion | ~6% – 10% | Anti-aging demand, personalized medicine |
| Testosterone (TRT) | $1.9 Billion | $2.5 Billion | ~4.2% | Men’s health awareness, online clinics growth |
GLP-1 Agonists: Huge Market Potential
GLP-1s (Semaglutide, Tirzepatide) are the primary drivers of the injectable wellness market. Initially developed for diabetes, their expansion into weight loss has caused exponential growth.
- Telehealth Integration: Direct-to-consumer platforms have lowered barriers, bringing treatments into the mainstream.
- Compound Growth: Supply shortages have fueled the growth of compounded GLP-1 markets.
Peptides: The “Biohacker” Favorite
Peptides like BPC-157, CJC-1295, and PT-141 are emerging as the next frontier in performance and longevity optimization.
- Anti-aging and recovery solutions
- Personalized medicine and targeted therapies
- Growing demand in private longevity markets
- High growth potential in metabolic and gastrointestinal health
Projected growth in specialized peptide markets is expected to exceed 20% CAGR in key wellness segments.
Peptide Applications
NEUROLOGICAL
WEIGHT LOSS
SECRETAGOGUES
Here are the top 5 peptides currently being marketed, categorized by their primary clinical focus:
1. BPC-157 (The "Wolverine" Peptide)
Often considered the cornerstone of regenerative peptide therapy, BPC-157 (Body Protection Compound) is primarily marketed for its rapid "accelerated healing" properties.
Primary Benefits: Repairs soft tissue (tendons, ligaments, and muscle), reduces systemic inflammation, and promotes "angiogenesis" (the formation of new blood vessels).
Marketed Use: It is the go-to for sports injuries, post-surgical recovery, and increasingly for gut health (treating "leaky gut" and IBS).
2. CJC-1295 + Ipamorelin (The Anti-Aging Duo)
These two are almost always marketed as a "stack" because they work synergistically to stimulate the pituitary gland to release natural Growth Hormone (GH).
Primary Benefits: Enhances deep (REM) sleep, increases lean muscle mass, decreases body fat, and improves skin elasticity/collagen production.
Marketed Use: This is the flagship "longevity" protocol for patients over 30 looking to reverse age-related decline in energy and muscle tone without the side effects of synthetic HGH.
3. MOTS-c
In 2026, MOTS-c (a mitochondrial-derived peptide) is the fastest-growing "new" entry, marketed as an "exercise mimetic" that improves metabolic flexibility and cellular energy, making it popular for those looking to enhance athletic endurance and insulin regulation.
Retatrutide is currently being marketed as the "triple agonist" and is widely considered the next major breakthrough in the metabolic and wellness injectable market. While drugs like Ozempic (Semaglutide) target one receptor and Mounjaro (Tirzepatide) targets two, Retatrutide targets three distinct pathways: GLP-1, GIP, and Glucagon.
4. TB-500 (Thymosin Beta-4)
If BPC-157 is for structural repair, TB-500 is for flexibility and inflammation. It is a synthetic version of a naturally occurring protein found in high concentrations in blood platelets.
Primary Benefits: Exceptional for reducing joint pain and stiffness, increasing range of motion, and supporting the immune system’s response to injury.
Marketed Use: It is often paired with BPC-157 in "Recovery Packs" for athletes or aging adults looking to maintain high levels of physical activity.
5. PT-141 (Bremelanotide)
This peptide is unique because it acts on the central nervous system rather than the vascular system, making it the top-marketed choice for sexual wellness.
Primary Benefits: Significant increase in libido and sexual desire for both men and women; effective for erectile dysfunction where traditional phosphodiesterase inhibitors (like Viagra) have failed.
Marketed Use: It is marketed as a "lifestyle" peptide for couples looking to revitalize their intimacy or for individuals managing hormone-related sexual dysfunction.
Testosterone (TRT): Normalizing Men's Wellness
Testosterone replacement therapy is transitioning from a niche treatment into a mainstream component of male health and wellness.
- Dominance of Injectables: Injectables account for 38–40% of the TRT market due to stability and effectiveness.
- E-Commerce Growth: Subscription-based online TRT services are rapidly expanding access and convenience.
Online clinics and telehealth platforms are expected to outpace traditional providers through 2030.
Emerging Trend: The "Med-Spa" Consolidation
A key shift over the next five years is the consolidation of wellness therapies into single integrated platforms. Clinics that traditionally focused on cosmetic treatments are now expanding into GLP-1 weight loss programs and hormone optimization.
This “lifestyle injectable” model is increasing patient lifetime value while creating recurring revenue streams across multiple treatment categories.
The medical spa segment is projected to grow at approximately 12% annually through 2030.
PEPTIDES
NEUROLOGICAL
WEIGHT LOSS
SECRETAGOGUES
Overcoming Barriers to Telehealth Access
While telehealth offers many benefits, there are still barriers that prevent patients from accessing virtual care. These barriers can include limited internet access lack of technical skills, and concerns about privacy and security.
Addressing these challenges requires investment in technology, education, and policy improvements to ensure equitable access for all patients.
Challenges & Solutions
Market Size
The global telehealth market reached approximately $285 billion in 2026 and is projected to grow to over $680 billion by 2030, at a CAGR of 24.3%, driven by the increasing demand for chronic disease management and the widespread adoption of hybrid care models.
In the United States, the market is valued at approximately $51 billion in 2025 and is expected to expand to $84 billion by 2030.
Cancer Testing Intellectual Property
Exosomal Delivery Platform for Therapy: A comprehensive system for the delivery of gene expression modulating agents for therapy against cancer and viral infection, with patent applications pending across multiple critical jurisdictions, including the U.S., Canada, China, Europe, and Japan.
- Increased NEAR-IR ISGL as a diagnostic cancer marker
- Advanced tissue diagnostics for multiple cancer types
- Focus on cell-free DNA (cfDNA) screening technology
- Improved early detection capabilities
Biotech Asset Held
Exousia Bio is a clinical stage biotech developing an exosomal treatment for Glioblastoma.
- Increased NEAR-IR ISGL as a diagnostic cancer marker
- Advanced tissue diagnostics for multiple cancer types
- Focus on cell-free DNA (cfDNA) screening technology
- Improved early detection capabilities
